-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Krystal Biotech, Lowers Price Target to $375

Benzinga·11/03/2026 15:02:38
语音播报
RBC Capital analyst Lisa Walter maintains Krystal Biotech (NASDAQ:KRYS) with a Outperform and lowers the price target from $400 to $375.